Quintrio
Home

LABORATORY ANALYTICAL INSTRUMENTS

Avantor, Inc.

AVTR

Avantor Inc provides products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company operates through two segments: Laboratory Solutions and Bioscience Production. It offers materials & consumables, equipment & instrumentation, and services & specialty procurement. Product groups include Equipment & Instrumentation, Services & Specialty Procurement, Proprietary Materials & Consumables, and Third-Party Materials & Consumables. Materials & consumables include high-purity chemicals and reagents, lab supplies, customized excipients, single-use assemblies, chromatography products, sample preparation kits, and fluid handling solutions. It operates in the Americas, Europe, and AMEA.

Last trade $15.19
Day change -$0.135 (-0.88%)
Day range $15.11 – $15.56
Volume 3,139,290
Market cap $10.38B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$10.38B
Price / earnings
30.79×
Price / book
1.78×
Price / sales
1.56×
EV / sales
2.05×
EV / EBITDA
14.96×

Profitability

Earnings per share
$0.50
Return on assets
2.9%
Return on equity
5.78%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.64×
Current ratio
1.89×
Quick ratio
1.27×
Cash ratio
0.34×

Cash flow

Price / cash flow
17.75×
Price / free cash flow
23.64×
Free cash flow
$439.2M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for AVTR, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$1.7B$1.69B$1.58B$1.66B$1.62B$1.68B$1.58B$1.69B
Cost of revenue$1.16B$1.16B$1.08B$1.14B$1.1B$1.13B$1.05B$1.12B
Gross profit$534.8M$537M$500.7M$523.9M$526.5M$554.1M$534.9M$562.9M
Selling, general and administrative$395.3M$415.2M$401.2M$392.4M$390.3M$425.3M$387.5M$371.4M
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$395.3M$415.2M$401.2M$392.4M$1.18B$425.3M$387.5M$371.4M
Operating income$139.5M$121.8M$99.5M$131.5M-$648.8M$128.8M$147.4M$191.5M
Interest expense-$39.9M-$39.4M-$42.9M-$40M-$44.2M-$43.4M-$42.2M-$44.9M
Income before taxes$98M$81.2M$55.5M$80.8M-$689.5M$81.7M$85.7M$584.2M
Income taxes-$105.4M$43.1M$12.2M$28.4M$22.3M$17M$21.2M$83.8M
Net income$203.4M$38.1M$43.3M$52.4M-$711.8M$64.7M$64.5M$500.4M
Net income attributable to common shareholders$203.4M$38.1M$43.3M$52.4M-$711.8M$64.7M$64.5M$500.4M
EBITDA$244.8M$227.4M$204.5M$234.8M$240.7M$231.5M$247.1M$292.4M
Basic earnings per share$0.30$0.06$0.06$0.08-$1.04$0.09$0.09$0.74
Diluted earnings per share$0.30$0.06$0.06$0.08-$1.04$0.09$0.09$0.74

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Avantor, Inc. (AVTR) is a Great Momentum Stock: Should You Buy?

Avantor, Inc. (AVTR) has earned a Zacks Momentum Style Score of A and a #2 (Buy) rating. The stock has outperformed its industry significantly, rising 5.3% weekly and 50.95% annually compared to the S&P 500's 13.12% yearly gain. Recent positive earnings estimate revisions for both current and next fiscal year support the bullish outlook.

Zacks Investment Research

Avantor (AVTR) Upgraded to Buy: What Does It Mean for the Stock?

Avantor, Inc. (AVTR) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company is positioned in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation driven by improving business fundamentals and positive earnings estimate revisions.

Zacks Investment Research

Avantor, Inc. (AVTR) Surpasses Q3 Earnings and Revenue Estimates

Avantor (AVTR) reported Q3 2026 earnings of $0.22 per share, beating consensus estimates of $0.21, with revenues of $1.7 billion exceeding expectations by 3.53%. The company has outperformed the market by 49.5% year-to-date. However, it received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market. The Medical Services industry ranks in the bottom 40% of Zacks industries.

Zacks Investment Research

Here's Why You Should Add Avantor Stock to Your Portfolio for Now

Avantor (AVTR) reported strong second-quarter 2026 results with raised 2026 guidance, driven by VWR segment's return to 1.7% organic growth and BMP's double-digit order growth. However, BMP's continued 5.6% organic revenue decline and uneven demand recovery remain concerns. The company's Revival program shows execution improvements across commercial performance and operations.

Zacks Investment Research

Progyny (PGNY) Soars 6.3%: Is Further Upside Left in the Stock?

Progyny (PGNY) shares surged 6.3% following positive insights from its annual selling season, with the company expecting to add 1.2 million new covered lives through the first half of 2027. The fertility benefits provider is projected to report quarterly earnings of $0.51 per share (+13.3% YoY) and revenues of $339.72 million (+8.4% YoY). However, unchanged earnings estimate revisions over the past 30 days suggest the recent rally may lack sustained momentum.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.